Biocon Ltd

Biocon's Growth Outlook: 13-15% Annual Revenue Rise & Stronger Margins 📈

- Revenue growth expected at 13-15% annually, driven by biosimilars.

- EBITDA projected to rise to approximately INR 45 billion by fiscal 2027 from INR 34 billion in fiscal 2025.

- EBITDA margins expected to remain stable at 22-23%.

- FFO to debt ratio forecast to improve to about 30% by fiscal 2027 from less than 10% in fiscal 2025.

- New product launches include bStelara, Aflibercept, and Denosumab in key markets.

- Adjusted debt estimated to drop to INR 115 billion in fiscal 2026 from INR 248 billion in fiscal 2025.

- Biocon Biologics has 10 commercialized biosimilars and a pipeline of over 20 assets, serving 6.3 million patients in 120+ countries.